In the United States, Moderna and Johnson & Johnson have received approval for booster shots.
On October 21, the US Food and Drug Administration (FDA) approved Moderna and Johnson & Johnson’s emergency use of booster dosages against the Covid-19 epidemic.
In a statement, the FDA said it has approved the “use of each of the available Covid-19 vaccines as a heterologous (or mix and match’) booster dose ineligible individuals following completion of primary vaccination with a different available Covid-19 vaccine after completion of primary vaccination with a different available Covid-19 vaccine.”
Individuals 18 years of age and older may receive a single booster dose of the Johnson & Johnson vaccine at least two months after completing the single-dose initial regimen, according to the government.
Meanwhile, those over the age of 65, as well as those over the age of 18 who work in dangerous industries, can receive a single booster dosage of the Moderna shots at least six months following the second dose.
The FDA is likely to make a decision on whether or not to approve the Pfizer-BioNTech vaccine for children aged 5 to 11 in the coming weeks.
On Wednesday, the White House announced a proposal to vaccinate youngsters aged 5 to 11 against the coronavirus.
“We know vaccines work because millions of adolescents aged 12 to 17 have been safely vaccinated,” the White House stated in a statement. “Those who have been fully vaccinated are ten times less likely to be hospitalized with COVID-19 and have a good level of protection, including against the Delta form.”
If approved by the FDA and recommended by the Centers for Disease Control and Prevention (CDC), President Joe Biden’s administration has enough shots to vaccinate the 28 million children aged 5-11 years old with a single dosage of the Pfizer-BioNTech vaccine.
The government also announced a collaboration with the Children’s Hospital Association to set up vaccination sites at more than 100 children’s hospital systems around the United States from November to December.
The FDA’s advisory committee meeting on Oct. 26 and the CDC’s meeting on Nov. 2-3 will decide whether or not to vaccinate children aged 5 to 11.
According to the White House, 189 million Americans, or two out of every three eligible persons, are fully vaccinated.